Royalty Pharma (FRA:RPD) Other Current Payables: €76 Mil (As of Mar. 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
68 GF Score
Price €52.78
GF Value €34.59
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Other Current Payables?

Royalty Pharma FRA:RPD +6.69% 68 Other Current Payables is €76 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 68/100 and a GF Value™ of €34.59 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's Other Current Payables for the quarter that ended in Mar. 2026 was €76 Mil.

Royalty Pharma's quarterly Other Current Payables declined from Sep. 2025 (€66 Mil) to Dec. 2025 (€62 Mil) but then increased from Dec. 2025 (€62 Mil) to Mar. 2026 (€76 Mil).

Royalty Pharma's annual Other Current Payables declined from Dec. 2023 (€76 Mil) to Dec. 2024 (€72 Mil) and declined from Dec. 2024 (€72 Mil) to Dec. 2025 (€62 Mil).

Royalty Pharma Other Current Payables Related Terms

Royalty Pharma Other Current Payables Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Other Current Payables Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only 95.52 89.49 76.25 72.40 62.19

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.64 85.14 65.79 62.19 75.62
FRA:RPD
68GF Score
Royalty Pharma PLC FRA:RPD
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €76 Mil mean?
Royalty Pharma (FRA:RPD) has a Other Current Payables of €76 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Other Current Payables too high?
Royalty Pharma's current Other Current Payables is €76 Mil. Overall, Royalty Pharma has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Other Current Payables compare to ROIV and MRNA?
Royalty Pharma's Other Current Payables of €76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Other Current Payables is €76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €34.59, compared to a current price of €52.78 — trading 52.6% above its estimated fair value. The current Other Current Payables is €76 Mil. Royalty Pharma's overall GF Score™ is 68/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Other Current Payables is €76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €52.78 is trading 52.6% above its estimated GF Value™ of €34.59. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Other Current Payables: €76 Mil
  • GF Value™: €34.59 vs. price of €52.78 (52.6% above fair value)
  • GF Score™: 68/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
68GF Score

Get the complete analysis for FRA:RPD

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€52.78
Price
€34.59
GF Value